Related references
Note: Only part of the references are listed.Altered Microenvironment Promotes Progression of Preinvasive Breast Cancer: Myoepithelial Expression of αvβ6 Integrin in DCIS Identifies High-risk Patients and Predicts Recurrence
Michael D. Allen et al.
CLINICAL CANCER RESEARCH (2014)
A human monoclonal antibody 264RAD targeting αvβ6 integrin reduces tumour growth and metastasis, and modulates key biomarkers in vivo
C. Eberlein et al.
ONCOGENE (2013)
Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer
Andrea L. A. Wong et al.
INTERNATIONAL JOURNAL OF BREAST CANCER (2012)
HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies
Devika Gajria et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2011)
Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer
Maggie C. U. Cheang et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Regulation of in situ to invasive breast carcinoma transition
Min Hu et al.
CANCER CELL (2008)
Antibody-mediated blockade of integrin αvβ6 inhibits tumor progression in vivo by a transforming growth factor-β-regulated mechanism
Louise A. Koopman Van Aarsen et al.
CANCER RESEARCH (2008)
The PI3K/Akt pathway: Recent progress in the development of ATP-competitive and allosteric Akt kinase inhibitors
Craig W. Lindsley et al.
CURRENT CANCER DRUG TARGETS (2008)
Overexpression of the αvβ6 integrin in cervical squamous cell carcinoma is a prognostic factor for decreased survival
S. Hazelbag et al.
JOURNAL OF PATHOLOGY (2007)
A peptide selected by biopanning identifies the integrin αvβ6 as a prognostic biomarker for nonsmall cell lung cancer
Anissa N. Elayadi et al.
CANCER RESEARCH (2007)
Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance
Emad A. Rakha et al.
EUROPEAN JOURNAL OF CANCER (2006)
HER2/Neu (ErbB2) signaling to Rac1-Pak1 is temporally and spatially modulated by transforming growth factor β
Shizhen Emily Wang et al.
CANCER RESEARCH (2006)
Activated type I TGFβ receptor kinase enhances the survival of mammary epithelial cells and accelerates tumor progression
R. S. Muraoka-Cook et al.
ONCOGENE (2006)
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
MJ Piccart-Gebhart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
EH Romond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
REporting recommendations for tumour MARKer prognostic studies (REMARK)
LM McShane et al.
EUROPEAN JOURNAL OF CANCER (2005)
Transcriptional activation of integrin β6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma
RC Bates et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Expression of luminal and basal cytokeratins in human breast carcinoma
DMA El-Rehim et al.
JOURNAL OF PATHOLOGY (2004)
Increased malignancy of neu-induced mammary tumors overexpressing active transforming growth factor beta 1
RS Muraoka et al.
MOLECULAR AND CELLULAR BIOLOGY (2003)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Share Paper
